The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX ...
Thank you to all my dedicated ‘Switchies’ for sticking around! Here's your social and governance wrapped for the year. Stay tuned for a look back on the top environment themes of the year tomorrow.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results